Liver fibrosis stage predicts early treatment outcomes with peginterferon plus ribavirin in HIV/hepatitis C virus co-infected patients

Andrea De Luca, Simona Di Giambenedetto, Antonella Cingolani, Adriana Ammassari, Giuseppe Marasca, Mario Tumbarello, Massimo Fantoni, Enrica Tamburrini, Roberto Cauda

Research output: Contribution to journalArticlepeer-review

Abstract

Thirty-six HIV-infected patients with chronic hepatitis C treated with peginterferon alpha-2a or 2b plus ribavirin were analysed in a prospective observational study. There were 15 (42%) treatment discontinuations; by intent-to-treat virological responders were 19 (53%) at week 24. A higher fibrosis score predicted premature discontinuation of hepatitis C virus (HCV) therapy and a lack of early virological response. Female sex and HCV genotype predicted early virological responses. Results support the early treatment of HCV in co-infected individuals.

Original languageEnglish
Pages (from-to)1602-1604
Number of pages3
JournalAIDS (London, England)
Volume18
Issue number11
DOIs
Publication statusPublished - Jul 23 2004

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Liver fibrosis stage predicts early treatment outcomes with peginterferon plus ribavirin in HIV/hepatitis C virus co-infected patients'. Together they form a unique fingerprint.

Cite this